Augmented reality (SKIA-Breast) localization for guiding breast-conserving surgery
Official title: Multicenter, Randomized, Controlled, Prospective, Confirmatory Study to Evaluate the Clinical Efficacy of Augmented Reality (AR)-Based Breast Cancer Medical Imaging Solution (SKIA-Breast) Localization Method in Breast Cancer Patients Confidential Statement
Run by SKIA Inc. · NCT07003841 · Data updated 2026-11-12
The trial will test whether an augmented reality system (SKIA-Breast) can guide breast-conserving surgery as well as conventional ultrasound skin marking for women with a single, biopsy-proven invasive breast tumor 5–30 mm in size.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 19 Years to 80 Years |
| Sex | Women only |
| Enrollment | 94 (estimated) |
| Sponsor | SKIA Inc. Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Seoul, Gangseo-gu and 2 other locations) |
| Status | Recruiting |
| Started | November 19, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | March 31, 2027 |
| Registry record updated | March 12, 2026 |
| Trial ID | NCT07003841 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women 19–80 years old with a single, biopsy-confirmed invasive breast cancer measuring 5–30 mm who are scheduled for breast-conserving surgery, have no distant metastases, and have undergone MRI, CT, and ultrasound.
✕Probably not a fit
Patients with multifocal disease, tumors smaller than 5 mm or larger than 30 mm, those who received neoadjuvant chemotherapy, have distant metastases, or cannot undergo MRI/CT/ultrasound are unlikely to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter, randomized 1:1 trial compares an AR-based imaging localization method (SKIA-Breast) to conventional ultrasound-guided skin marking for women undergoing breast-conserving surgery. Eligible participants are women aged 19–80 with a single invasive breast tumor sized 5–30 mm who have undergone MRI, CT, and ultrasound and have not received neoadjuvant chemotherapy. Surgeons will use the assigned localization method during the operation, and the primary endpoint is the negative margin resection rate determined by histopathology, with re-excision rate as a secondary outcome. The trial is conducted across several tertiary centers in Seoul to test non-inferiority of the AR guidance versus standard ultrasound skin marking.
Why it matters
Potential benefit: If successful, SKIA-Breast could provide real-time, non-invasive tumor visualization that maintains or improves negative margin rates and reduces the need for re-excision.
How similar studies have gone: Small feasibility and pilot studies of AR-guided surgical navigation in other surgical fields and preliminary breast applications have shown promise, but randomized evidence in breast-conserving surgery remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects will be enrolled only when all the inclusion criteria are fully met. 1. Subjects who aged 19 to 80 years diagnosed with breast cancer through biopsy. 2. Subjects diagnosed with breast cancer who had both MRI and CT and ultrasound scans. 3. Patients diagnosed with breast cancer who are scheduled to undergo breast-conserving surgery, have not received neoadjuvant chemotherapy, and show no evidence of metastasis to other organs. 4. Tumor size criteria on ultrasound: : 5 mm ≤ tumor size ≤ 30 mm 5. Subjects whose biopsy pathology results are Invasive carcinoma. 6. Subjects who have a single lesion. 7. Subjects who have received a full explanation of the clinical trial fully understand its details, voluntarily decide to participate, and provide written informed consent. Exclusion Criteria: * Subjects will be excluded from enrollment if they meet any of the exclusion criteria. 1. Subjects prohibited from both MRI, CT and Ultrasound scans. 2. Subjects with no lesions visible on CT. 3. Pregnant or lactating(i.e., breastfeeding) subjects. 4. Subjects who are biologically male. 5. Subjects with breast cancer who received neoadjuvant chemotherapy or who have metastasized to other organs 6. Subjects whose biopsy pathology results are Invasive lobular carcinoma 7. Subjects deemed unsuitable for the study according to judgment of the investigator
Where it's running
-
Ewha Womans University Medical Center
Seoul, Gangseo-gu, South Korea Recruiting -
Seoul National University Hospital
Seoul, Jongno-gu, South Korea Recruiting -
Yonsei University Health System, Severance Hospital
Seoul, Seodaemun-gu, South Korea Recruiting
Study contacts
- Study coordinator: Jeongmi LEE
- Email: jmlee@skia.kr
- Phone: +821048856620
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Improved Facial Skin Quality After VYC-12L for Breast Cancer Survivors
This study tests whether intradermal injections of VYC-12L can improve facial skin quality and quality of life in adults who have completed breast cancer treatment.
-
Breast cancer subtypes and outcomes in Colombian women
This study looks back at medical records of women with breast cancer to see how different molecular subtypes relate to survival and recurrence in a single Colombian hospital.
-
Multimodal psychosomatic symptom care for breast cancer: personalized acupuncture care guided by shared decision-making
This study tests whether personalized acupuncture options (manual acupuncture, ear acupuncture, or both) can help women with breast cancer who have anxiety, sleep problems, or fatigue, compared to routine nursing care.
-
Slow Jogging for Breast Cancer Survivors
This study tests whether a 12-week slow jogging program helps sleep quality in women who have completed breast cancer treatment.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
Benchmarking AI language models against tumor boards for oncology treatment decisions
This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.